Next Generation Innate Immune Checkpoint Inhibitor Platform Lead Clinical Candidate RRx-001
First-generation therapies, which target “checkpoint inhibitors”, have revolutionized the treatment of cancer, but only a small set of patients derives benefit. One of the reasons that not all patients respond to treatment is the presence of myeloid-derived suppressor cells in the tumor microenvironment.
Multimechanistic RRx-001 is a next generation innate immune checkpoint inhibitor that targets the CD-47-SIRPα axis and repolarizes tumor associated macrophages (TAMs) and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype.
RRx-001 was recently granted orphan drug designation for SCLC and neuroendocrine cancer in the US by the FDA and for SCLC in Europe by the EMA.
RRx-001 Phase 3 clinical trials will launch in 2018 for eligible patients with SCLC, neuroendocrine cancer, high grade neuroendocrine prostate cancer and ovarian cancer.
For further information about RRx-001, please contact us at email@example.com.
For information about currently enrolling clinical trials featuring RRx-001, please visit our Clinical Trials page.
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer